The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
REGULATORY
JGA Calls for Elimination of Price Bracket Grouping Rule for Listed Generics
Itsuro Yoshida, president of the Japan Generic Medicines Association (JGA), made three requests including the abolition of the three price-bracket grouping rule for generics that have already been listed at a key drug pricing panel on May 17. At a…
To read the full story
Related Article
- Maintain Prices for On-Patent Drugs, Off-Year Revisions Should Only Cover Limited Products: FPMAJ
May 19, 2017
- JPWA Calls for Off-Year Surveys Covering All Products: Chuikyo Hearing
May 19, 2017
- FPMAJ, EFPIA See Need to Revisit Cost-Based Pricing Method: Chuikyo
May 18, 2017
- (Update) 3 Pharma Groups Push for Price Maintenance during Patent Term: Chuikyo Hearing
May 18, 2017
- Japan Drug Market Could Shrink Annual 1.5% by FY2026: EFPIA Simulation
May 17, 2017
- Continue Price Maintenance Scheme without Shedding Eligible Products: PhRMA
May 17, 2017
- 3 Pharma Groups Push for Price Maintenance during Patent Term: Chuikyo Hearing
May 17, 2017
REGULATORY
- Chuikyo Reps Back More Pharma Access to CEA Deliberations, Urge Neutrality
October 29, 2026
- FY2027 Revision: HCPs Press for Action on Drug Shortages, Negative Margins
October 29, 2026
- Zolgensma Cost-Effectiveness Analysis to Resume after Five-Year Halt
October 29, 2026
- Japan Eyes Priority Review for MCMs, Bill Submission Planned for 2027
October 28, 2026
- Panel Member Urges Review of Tavneos Blue Letter Timing
October 28, 2026
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…